__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

European Society of Cardiology (ESC). 2021 Guidelines on Cardiovascular Disease Prevention in Clinical Practice

This link will take you to the ESC website, which is a non-Novartis website.

Visit

 

National Institute for Health and Care Excellence (NICE). Cardiovascular Disease: Risk Assessment and Reduction, including Lipid Modification. Clinical Guideline [CG181]

This link will take you to the NICE website, which is a non-Novartis website.

Visit

 

National Health Service (NHS) England. Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD

This link will take you to the NHS website, which is a non-Novartis website.

Visit

 

Scottish Intercollegiate Guidelines Network (SIGN). Risk Estimation and the Prevention of Cardiovascular Disease. National Clinical Guideline [SIGN 149]

This link will take you to the SIGN website, which is a non-Novartis website.

Visit

Rate this content: 
No votes yet
UK | November 2021 | 164039
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]